AT1391 is a daily insulin skin patch designed to provide continuous basal levels of insulin for patients with diabetes.
- Mechanism
- Curator reviewed
Insulin binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor is able to autophosphorylate and phosphorylate numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. These activated proteins, in turn, lead to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC) which play a critical role in metabolism and catabolism.
- Primary indication
- Investigated for use/treatment in diabetes mellitus type 1 and 2.Curator reviewed
- Code names
- AT1391
Resolves to
What you can answer from here — as of April 02, 2025
Which drugs share a target with AT1391, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account